No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for ...

Moderna MRNA announced that its seasonal influenza vaccine ... terminated contracts worth $766 million awarded to the company for the late-stage development of an mRNA-based bird flu vaccine, ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna’s award for late-stage development of pre-pandemic influenza vaccines.

Moderna had already started a Phase 1/2 trial of its bird flu (H5N1) vaccine and reported strong early results. (HealthDay News) — The U.S. government has canceled a $600 million contract with ...

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine that could be used to treat bird flu in people, as concern grows about ...

Phase 1/2 H5 avian flu vaccine study shows positive interim results. Company has been notified that HHS will terminate Moderna’s award for late-stage development of pre-pandemic influenza vaccines.

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial.

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial.